Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Assets: 2012-2024

Historic Non-Current Assets for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to $339.5 million.

  • Ptc Therapeutics' Non-Current Assets rose 13.41% to $635.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $635.9 million, marking a year-over-year increase of 13.41%. This contributed to the annual value of $339.5 million for FY2024, which is 49.86% down from last year.
  • Ptc Therapeutics' Non-Current Assets amounted to $339.5 million in FY2024, which was down 49.86% from $677.1 million recorded in FY2023.
  • Over the past 5 years, Ptc Therapeutics' Non-Current Assets peaked at $1.0 billion during FY2022, and registered a low of $339.5 million during FY2024.
  • For the 3-year period, Ptc Therapeutics' Non-Current Assets averaged around $676.1 million, with its median value being $677.1 million (2023).
  • Its Non-Current Assets has fluctuated over the past 5 years, first rose by 15.63% in 2020, then slumped by 49.86% in 2024.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Non-Current Assets stood at $976.5 million in 2020, then increased by 0.73% to $983.7 million in 2021, then climbed by 2.86% to $1.0 billion in 2022, then slumped by 33.08% to $677.1 million in 2023, then tumbled by 49.86% to $339.5 million in 2024.